Klinefelter Syndrome Clinical Perspectives and Treatments

Klinefelter syndrome (47,XXY) is the most common male sex chromosome aneuploidy, affecting approximately 1 in 500–1,000 live male births. Clinically, it is characterised by testicular dysgenesis, androgen deficiency, tall stature, and variable neurocognitive and psychosocial features. Hypogonadism underlies many somatic and metabolic comorbidities, including osteoporosis, metabolic syndrome and insulin resistance. Infertility is near universal, though focal spermatogenesis may permit assisted‐reproductive techniques. Testosterone replacement therapy remains the cornerstone of endocrine management, commencing at puberty to induce and maintain secondary sexual characteristics, optimise bone and muscle health and support psychosocial well-being. Early diagnosis—facilitated by awareness of developmental delays, cryptorchidism or learning difficulties—enables timely intervention with speech, educational and psychosocial support. Advances in molecular profiling are illuminating the epigenetic and transcriptomic alterations that contribute to testicular degeneration, immune modulation and neurocognitive risk, offering prospects for targeted therapies. Multidisciplinary care, integrating endocrinology, fertility specialists, psychologists and genetic counsellors, is essential to address the heterogeneous needs of individuals across the lifespan.

Research from Nature Portfolio

Recent studies have leveraged genome-wide approaches to define the molecular underpinnings of Klinefelter syndrome. A comprehensive epigenetic-transcriptomic analysis of peripheral blood cells revealed a distinct methylation signature across autosomes and the X chromosome, correlating DNA methylation with aberrant expression of genes implicated in immune regulation, Wnt signalling and neuronal development. This work has identified novel candidate genes and long non-coding RNAs that may drive the multisystem phenotype of 47,XXY individuals. In parallel, a genome-first investigation into sex chromosome aneuploidies has modelled the differential effects of extra X and Y chromosomes on neurodevelopmental risk, demonstrating that Y-chromosome dosage confers a greater predisposition to certain neuropsychiatric traits than X dosage. This framework refines our understanding of cognitive and behavioural dimensions in Klinefelter syndrome and may guide personalised risk assessment and support strategies.

Klinefelter Syndrome Clinical Perspectives and Treatments publication trend

The graph below shows the total number of articles in klinefelter syndrome clinical perspectives and treatments across all publications each year (not limited to Nature Index journals).

Technical terms

Aneuploidy: The presence of an abnormal number of chromosomes in a cell.

Hypogonadism: Reduced or absent secretion of sex hormones from the gonads.

Sertoli cell: A supporting cell in the testis essential for germ cell development and blood-testis barrier formation.

Leydig cell: A testicular cell type responsible for testosterone synthesis.

Epigenetic profiling: Genome-wide analysis of chemical modifications to DNA and associated proteins that regulate gene expression without altering the DNA sequence.

X-chromosome inactivation: The process by which one of the two X chromosomes in females (or supernumerary Xs in aneuploidy) is largely silenced to equalise gene dosage.

References

1. A genome-first study of sex chromosome aneuploidies provides evidence of Y chromosome dosage effects on autism risk. Nature Communications (2024).
2. X‑chromosome loss rescues Sertoli cell maturation and spermatogenesis in Klinefelter syndrome. Cell Death & Disease (2024).
3. Klinefelter syndrome (KS): genetics, clinical phenotype and hypogonadism. Journal of Endocrinological Investigation (2016).
4. DNA hypermethylation and differential gene expression associated with Klinefelter syndrome. Scientific Reports (2018).
5. Deregulation of sertoli and leydig cells function in patients with klinefelter syndrome as evidenced by testis transcriptome analysis. BMC Genomics (2015).